Patent ID: 7419995

Claim:
A compound represented by Formula (I) or a pharmaceutically acceptable salt or N-oxide thereof, wherein: R1 and R2 are independently: C 0-8 alkyl optionally substituted with a heterocyclyl group; C 0-8 alkyl optionally substituted with 1-6 independent halo, —CONR 11 R 12 , —NR 13 CONR 11 R 12 , —NR 13 CO 2 R 11 , —S(O) 0-2 NR 11 R 12 , —NR 11 S(O) 0-2 R 12 , CN, OH, or optionally substituted aryl groups; —C 0-8 alkyl-C 3-8 cycloalkyl; —C 0-8 alkyl-O—C 0-8 alkyl; —C 0-8 alkyl-N(C 0-8 alkyl) (C 0-8 alkyl); —C 0-8 alkyl-S(O) 0-2 —C 0-8 alkyl; or heterocyclyl optionally substituted with 1-4 independent C 0-8 alkyl, cyclyl, or substituted cyclyl groups; or R1 and R2, taken together with the nitrogen to which they are joined, form a heterocyclic group optionally substituted with 1-4 independent C 0-8 alkyl, —C 0-8 alkyl-O—C 0-8 alkyl, —C 0-8 alkyl-aryl, or —C 0-8 alkyl-heteroaryl groups, provided that the heterocyclic group formed is not piperazine; R3 is an aryl or hetaryl group, optionally substituted with 1-4 independent C 0-8 alkyl, C 0-8 alkyl-cyclyl, halo, OH, —NR 31 S(O) 0-2 R 32 , —S(O) 0-2 NR 31 R 32 , —NR 31 COR 32 , —NR 31 CONR 32 R 33 , —CONR 31 R 32 , S(O) 0-2 R 31 , —O-aryl, —O-hetaryl, NO 2 , CN, CF 3 , OCF 3 , or OCHF 2 groups; provided that R3 is not a tetrazolyl, 5-pyrimidinyl, or 4-biphenyl; R 11 , R 12 , R 13 , R 31 , R 32 , and R 33 are each independently: C 0-8 alkyl optionally substituted with a heterocyclyl group; C 0-8 alkyl optionally substituted with 1-6 independent halo, —CON(C 0-8 alkyl )(C 0-8 alkyl), —N(C 0-8 alkyl)CON(C 0-8 alkyl)(C 0-8 alkyl), —N(C 0-8 alkyl)CO 2 (C 0-8 alkyl), S(O) 0-2 N(C 0-8 alkyl)(C 0-8 alkyl), —NR 11 S(O) 0-2 (C 0-8 alkyl), CN, OH, or optionally substituted aryl groups; —C 0-8 alkyl-C 3-8 cycloalkyl; —C 0-8 alkyl-O—C 0-8 alkyl; —C 0-8 alkyl-N(C 0-8 alkyl)(C 0-8 alkyl); —C 0-8 alkyl-S(O) 0-2 —C 0-8 alkyl; or heterocyclyl optionally substituted with 1-4 independent C 0-8 alkyl, cyclyl, or substituted cyclyl groups.